TROP-2 and nectin-4 were initially added as the tumor targets for sacituzumab govitecan and enfortumab vedotin, meanwhile, it extended further to include HER2 as target for trastuzumab deruxtecan for better therapeutic index (20). Here, ERBB2 is linked to neoplasm.